Monkeypox drug trial shows promise: tecovirimat tested in 597 patients
NCT ID NCT05559099
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This study tested whether the drug tecovirimat is safe and effective for treating monkeypox (mpox) in adults and children. Participants received either tecovirimat or a placebo along with standard care for 14 days. The main goal was to see how quickly skin lesions healed. The trial included 597 people with confirmed monkeypox infection and at least one active lesion.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONKEYPOX are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
L'Hôpital Général de Référence de Kole
Kole, Democratic Republic of the Congo
-
L'Hôpital Général de Référence de Tunda
Tunda, Democratic Republic of the Congo
Conditions
Explore the condition pages connected to this study.